metaOBS - - Real World Evidence KB

Treatment relative effect with 95% CI; and degree of certainty (adaptated from GRADE). method

Treament	Trials	Summary Endpoints
Treament	Trials	clinical deterioration	clinical improvement	deaths	viral clearance
alpha lipoic acid	1	-	-	0.17 [0.02; 1.44], 1 RCT, I2=0% inconclusive result	-
aviptadil	1	-	-	-	-
pyridostigmine	1	-	-	0.33 [0.14; 0.79], 1 RCT, I2=0% unassessable degree of certainty	-
2-deoxy-D-glucose (2-DG)	0	-	-	-	-
acetylcysteine	0	-	-	-	-
anti-CK2	0	-	-	-	-
Aspirin	0	-	-	-	-
BLD-2660 (calpain inhibitor)	0	-	-	-	-
calcium channel blocker	0	-	-	-	-
camostat mesilate	0	-	-	-	-
Cannabidiol	0	-	-	-	-
continuous positive airway pressure (CPAP)	0	-	-	-	-
cytokine adsorption	0	-	-	-	-
diammonium glycyrrhizinate	0	-	-	-	-
dipyridamol	0	-	-	-	-
dornase alfa	0	-	-	-	-
expectorants and mucolytics	0	-	-	-	-
honey	0	-	-	-	-
kinin-kallikrein inhibitors	0	-	-	-	-
melatonin	0	-	-	-	-
mouthrise and gargling agents	0	-	-	-	-
N-Acetylcysteine	0	-	-	-	-
nasal spray	0	-	-	-	-
natural killer (NK) cells	0	-	-	-	-
nicotin	0	-	-	-	-
nigella sativa oil	0	-	-	-	-
nitric oxide (gas Inhalation or releasing solution)	0	-	-	-	-
omega-3 Polyunsaturated Fatty Acids	0	-	-	-	-
ozonated autohemotherapy	0	-	-	-	-
plasma exchange	0	-	-	-	-
povidone-iodine	0	-	-	-	-
previfenon (EGCG)	0	-	-	-	-
prostacyclin	0	-	-	-	-
PUL-042 inhalation solution	0	-	-	-	-
radiotherapy	0	-	-	-	-
sabizabulin	0	-	-	-	-
sildenafil	0	-	-	-	-
triiodothyronine (T3)	0	-	-	-	-